Envestnet Asset Management Inc. Acquires 6,659 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 5.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,186 shares of the medical equipment provider's stock after acquiring an additional 6,659 shares during the period. Envestnet Asset Management Inc. owned about 0.18% of Lantheus worth $12,121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Avantax Advisory Services Inc. boosted its holdings in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Lantheus during the 4th quarter worth about $237,000. Commonwealth Equity Services LLC boosted its holdings in shares of Lantheus by 39.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 10,814 shares of the medical equipment provider's stock worth $967,000 after buying an additional 3,045 shares during the period. Cibc World Markets Corp bought a new stake in shares of Lantheus during the 4th quarter worth about $576,000. Finally, Xponance Inc. boosted its holdings in shares of Lantheus by 4.6% during the 4th quarter. Xponance Inc. now owns 9,786 shares of the medical equipment provider's stock worth $875,000 after buying an additional 427 shares during the period. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Truist Financial reduced their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. William Blair restated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, B. Riley decreased their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.20.

Lantheus Price Performance

Shares of Lantheus stock traded up $0.97 on Wednesday, reaching $73.31. 600,771 shares of the stock were exchanged, compared to its average volume of 982,418. The firm's 50 day moving average is $78.40 and its 200-day moving average is $89.08. Lantheus Holdings, Inc. has a one year low of $69.12 and a one year high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The firm has a market cap of $5.07 billion, a PE ratio of 20.83 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the company posted $1.69 EPS. The business's revenue was up .8% on a year-over-year basis. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.